Judge Says Janssen Alzheimer's Patent Invalid

Law360, New York (August 28, 2008, 12:00 AM EDT) -- A federal judge has ruled that Janssen Pharmaceutica Inc.'s Alzheimer's drug patent is invalid for lack of enablement in a victory for several generic-drug makers accused of infringing the patent.

Judge Sue Robinson ruled against Janssen in the U.S. District Court for the District of Delaware in a consolidated case the company had filed against several generics makers over Alzheimer's drug Razadyne.

In 2005, the defendant drug companies filed abbreviated new drug applications with the U.S. Food and Drug Administration to make generic versions of the...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.